AbbVie Says Phase 3 Data On Risankizumab Shows Greater Impro

LONDON (dpa-AFX) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or

Related Keywords

London , City Of , United Kingdom , , American College Of Rheumatology Convergence , Boehringer Ingelheim , American College , Rheumatology Convergence , European Medicines Agency , Medicinal Products , Human Use , Abbvie , Ways , Hase , Data , Risankizumab , Shows , Greater , Improvements , Psoriatic , Arthritis , Signs ,